Longitudinal analysis at three oral sites links oral microbiota to 1

clinical outcomes in allogeneic hematopoietic stem-cell transplant 2

- Vitor Heidrich^{1,2}, Franciele H. Knebel¹, Julia S. Bruno¹, Vinícius C. de Molla^{3,4}, Wanessa 3
- 4 Miranda-Silva¹, Paula F. Asprino¹, Luciana Tucunduva⁵, Vanderson Rocha⁶, Yana Novis⁵,
- 5 Eduardo R. Fregnani¹, Celso Arrais-Rodrigues^{3,4}, Anamaria A. Camargo^{1,*}
- 6 ¹Centro de Oncologia Molecular, Hospital Sírio-Libanês, São Paulo, SP, Brazil
- 7 ²Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP,
- 8 Brazil
- 9 ³Hospital Nove de Julho, Rede DASA, São Paulo, SP, Brazil
- 10 ⁴Universidade Federal de São Paulo, São Paulo, SP, Brazil
- 11 ⁵Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, SP, Brazil
- 12 ⁶Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo/Instituto do Câncer do
- 13 Estado de São Paulo (ICESP), São Paulo, SP, Brazil
- 14 *Corresponding author
- 15 Authors' email addresses
- 16 VH: vheidrich@mochsl.org.br
- 17 FHK: fhknebel@mochsl.org.br
- 18 JSB: juliasb9@gmail.com
- 19 VCM: viniciuscamposdemolla@gmail.com
- 20 WMS: wmswanessa@yahoo.com.br
- 21 PFA: pasprino@mochsl.org.br
- 22 LT: luciana.tucunduva@gmail.com
- 23 VR: rocha.vanderson@hotmail.fr
- 24 YN: yananovis@yahoo.com
- 25 EFR: eduardofregnani@me.com
- 26 CAR: celsoarrais@gmail.com
- 27 AAC: anamaria.acamargo@hsl.org.br

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Abstract

29 Background

30 Allogeneic hematopoietic stem-cell transplant (allo-HSCT) is a potentially curative therapy 31 for several hematological disorders. Before stem-cell infusion, recipients undergo a 32 conditioning regimen with chemo/radiotherapy and immunosuppressants, requiring the use 33 of antibiotics to treat and prevent infections. This regimen promotes drastic alterations in the 34 recipient's microbiotas, including the oral microbiota, which have been associated with allo-35 HSCT complications and poor outcomes. However, long-term longitudinal studies on the oral 36 microbiota of allo-HSCT recipients are scarce and disregard the existence of distinct 37 microbiotas within the oral cavity. Here, we used 16S rRNA gene sequencing to characterize 38 the microbiota dynamics (during and after allo-HSCT) of 31 allo-HSCT recipients at 3 oral 39 sites (gingival crevicular fluid, oral mucosa, and supragingival biofilm).

40 Results

41 Analysis of the oral microbiota dynamics during allo-HSCT revealed a significant decline in 42 bacterial diversity and major shifts in microbiota composition in all oral sites, including 43 blooms of potentially pathogenic genera. These blooms in some cases preceded respiratory 44 infections caused by the blooming genera. We also noticed that differences in microbiota 45 diversity and composition between oral sites were lost during allo-HSCT. Overall, oral 46 microbiotas returned to their preconditioning state after engraftment. However, the ability to 47 recover the initial bacterial composition varied between patients. After stratifying patients based on their ability to recover their preconditioning microbiota composition, we found that 48 49 recovery of the oral mucosa microbiota composition was not associated with antibiotic usage 50 but was associated with higher preconditioning diversity and earlier reconstitution of normal 51 leukocyte counts. Most notably, oral mucosa microbiota composition recovery was an 52 independent biomarker of better allo-HSCT outcomes.

2

53 Conclusion

We observed clear patterns of microbiota dysbiosis in all three oral sites during allo-HSCT, however each oral site responded differently to the perturbations associated with allo-HSCT. Oral microbiota injury and recovery patterns were associated with allo-HSCT complications and outcomes. This study highlights the potential clinical impact of the oral microbiota in the allo-HSCT setting and the clinical value of tracking oral microbiota changes during allo-HSCT.

60 Keywords

61 Oral microbiome; 16S rRNA gene sequencing; allogeneic hematopoietic cell transplant;

62 microbiome stability; blooming of bacteria; biomarkers; clinical outcomes.

63 Introduction

64 Countless microbes from food, air, and our physical/biological environment arrive in 65 our mouths daily. However, only a small subset of these microbes can colonize the oral 66 cavity to compose the oral microbiota [1]. This constant contact with non-resident microbes 67 and frequent exposure to other insults (e.g., toothbrushing) made the human oral microbiota 68 remarkably stable and resilient to external perturbations [2].

Residing oral microbes organize in biofilms, creating oxygen gradients that allow colonization by both anaerobic and aerobic bacteria [1]. Differences in moisture, topography, and tissue type (shedding vs. non-shedding), among others, make each oral site home to distinct bacterial communities [1, 3] with main compositional differences existing between mucosa-associated and teeth-associated microbiotas [4].

These distinct oral microbiotas are important regulators of human health, as they have been associated with different local and systemic disorders [5]. While the supragingival biofilm is causally linked to the pathogenesis of dental caries [6], bacteria at the gingival crevice, an oxygen-limited environment bathed in immune exudate (gingival crevicular fluid), are linked to periodontitis [7] and may cause bacteremia by translocation to the circulation

across the thin gingival crevice epithelium [8]. Oral bacteria can further facilitate systemic
reach by producing molecules that increase vascular permeability [5]. Using this strategy,
oral *Porphyromonas gingivalis* is able to colonize the brain, contributing to the pathogenesis
of Alzheimer's disease [9].

83 Allogeneic hematopoietic stem-cell transplant (allo-HSCT) is used to treat malignant 84 (e.g., acute myeloid leukemia) and non-malignant (e.g., aplastic anemia) hematological 85 disorders [10]. The goal of allo-HSCT is to eradicate malignant/defective cells and to replace 86 an abnormal hematopoietic and immune system [11]. Allo-HSCT recipients undergo a 87 conditioning regimen with chemo/radiotherapy that reduces disease burden and provides 88 sufficient immunoablation to allow donor stem-cell engraftment [12]. After engraftment, the 89 graft-vs-tumor/autoimmunity effect further promotes disease eradication and the 90 hematopoietic/immune function gradually reconstitutes [13]. Besides chemo/radiotherapy, 91 allo-HSCT recipients are treated with immunosuppressants to prevent engraftment failure 92 and graft-vs-host disease, and antibiotics to prevent and treat opportunistic infections during 93 immunosuppression [13, 14].

94 Allo-HSCT is considered one of the most severe perturbations the immune system 95 undergoes in the therapeutic setting [15]. Since the immune system regulates microbiota 96 composition [16] and chemotherapy [17], radiotherapy [18], and antibiotics [19] have 97 detrimental effects on the microbiota, drastic alterations in the gut microbiota have been 98 reported in allo-HSCT recipients, including loss of bacterial diversity and blooms of 99 potentially pathogenic species [20]. Recent evidence shows these alterations extend to other 100 microbiotas [21], including the relatively more stable oral microbiota [22-26]. More 101 importantly, the pre-transplant microbiota and the extent of microbiota damage during allo-102 HSCT are associated with allo-HSCT complications and outcomes, so that gut and oral 103 microbiota provide biomarkers in the allo-HSCT setting [24, 25, 27–30].

104 The stability of the oral microbiota [5] and its associations with allo-HSCT outcomes 105 offer a unique opportunity to identify predictive biomarkers and develop therapeutic 106 interventions to promote oral health in allo-HSCT recipients, potentially improving allo-HSCT

4

107 safety and efficacy. However, so far, oral microbiota studies in allo-HSCT recipients 108 evaluated single oral sites, not leveraging the ease of sampling of different oral 109 compartments [22–26, 30]. In addition, although a causal link between post-transplant gut 110 microbiota recovery and improved clinical responses to allo-HSCT has been suggested [15], 111 oral microbiota recovery trajectories after allo-HSCT were not thoroughly characterized and 112 their association with allo-HSCT outcomes remain unknown.

113 To obtain a more in-depth understanding of oral microbiota dynamics during and 114 after allo-HSCT and to test whether oral microbiota recovery is associated with allo-HSCT 115 outcomes, we profiled the oral microbiota of a Brazilian cohort of allo-HSCT recipients. We 116 collected over 440 samples encompassing five timepoints and three oral sites: gingival 117 crevicular fluid (GCF), oral mucosa (OM), and supragingival biofilm (SB), which allowed a 118 longitudinal anatomically-aware analysis of the oral microbiota. We used 16S rRNA gene 119 sequencing to characterize diversity, compositional, and taxonomical changes in oral 120 microbiota during allo-HSCT and after engraftment. We associated these changes with 121 antibiotic usage and allo-HSCT complications. Finally, we evaluated recovery trajectories 122 after allo-HSCT to associate oral microbiota recovery with allo-HSCT outcomes.

123 Materials and methods

124 Patients' clinical characteristics

125 Thirty-one patients undergoing allo-HSCT at Hospital Sírio-Libanês (São Paulo, 126 Brazil) were recruited between January 2016 and April 2018. The median age was 50 years, 127 most patients were male (55%), and acute leukemia was the most common underlying 128 disease (58%; 11 acute myeloid leukemia and 7 acute lymphocytic leukemia cases). Most 129 patients underwent reduced intensity conditioning (61%) and received grafts from peripheral 130 blood (68%). Patient clinical information is summarized in Table S1.

5

131 Antibiotic usage analysis

132 Antibiotic prescriptions were retrieved retrospectively from clinical records. 133 Information spanning 30 days before preconditioning sampling and 100 days after stem-cell 134 infusion was collected to build timelines of antibiotic usage for each patient (Additional file 1: 135 Timelines of antibiotic usage). A ridgeline plot of antibiotic usage detailing all antibiotics and 136 antibiotic classes used showed antibiotics prescription concentrates in the few weeks 137 immediately after infusion (Fig. S1), with only 5/31 patients receiving antibiotics before 138 preconditioning (Additional file 1). Due to the sparse use of antibiotics before preconditioning 139 and the unlikely effect of antibiotics received months after allo-HSCT on clinical outcomes, 140 antibiotic usage was analyzed considering only the time window between preconditioning 141 and 30 days after engraftment (a patient deceased during this period was excluded from the 142 analysis). For each patient, the length in days under antibiotic therapy (length of therapy, 143 LOT) and the number of agent days under antibiotic therapy (days of therapy, DOT) was 144 calculated, as defined previously [31]. To evaluate the impact of specific antibiotic classes on 145 microbiota dynamics, patients were further classified according to antibiotic class usage 146 during the period of interest. Only antibiotic classes received by at least 20% of our patients 147 (6/30) were considered in this analysis. In addition to individual antibiotics prescriptions, all 148 patients underwent standard antimicrobial prophylaxis with antibiotic, antiviral and antifungal 149 drugs. Because the standard antibiotic prophylaxis protocol in our institution comprises oral 150 levofloxacin and sulfamethoxazole-trimethoprim, their use was not considered in the 151 antibiotic usage analysis.

152 Sample collection

Patients were examined frequently by an oral medicine specialist throughout the hospitalization period. The standard oral hygiene protocol comprised toothbrushing with fluoridated toothpaste and 0.12% chlorhexidine mouthwash. Samples were collected at least six hours after the last oral hygiene procedure by an oral medicine specialist at three oral

6

157 sites. GCF samples were collected by inserting absorbent paper points in the gingival 158 crevice; OM samples were collected by swabbing bilateral buccal mucosa, alveolar mucosa 159 of the jaws, and tongue dorsum; SB samples were collected by swabbing all vestibular 160 enamel surface. Samples were dry-stored at -20°C.

161 DNA extraction and 16S rRNA gene amplicon sequencing

Samples were brought to room temperature. Bacterial cells were recovered from swabs or paper points by vortexing in 600 µl or 800 µl TE buffer (10mM Tris; 1mM EDTA; pH 8,0), respectively. Samples were transferred to a new tube, supplemented with 6 µl (OM and SB) or 8 µl (GCF) PureLink[™] RNAse A (20 mg/ml; Invitrogen), and DNA was extracted using the QIAamp DNA Mini Blood kit (Qiagen) following the manufacturer's protocol (*Buccal Swab Spin Protocol*).

Bacterial communities were profiled by 16S rRNA gene amplicon-sequencing as described in detail previously [32]. In short, amplicon libraries were prepared with 12.5 ng of total DNA and pre-validated V3V4 primers [33] following Illumina's protocol (*Preparing 16S Ribosomal RNA Gene Amplicons for the Illumina MiSeq System*). Amplicons were sequenced on the Illumina MiSeq platform using the MiSeq Reagent Kit v3 (600-cycle) (Illumina).

174 **Bioinformatics pipeline**

175 Reads were demultiplexed using the MiSeq Reporter Software. Primers were 176 removed and low-quality 3' ends were trimmed using segtk [34]. Next, reads were processed 177 using QIIME 2 (v2019.10.0) as schematized in Fig. S2a [35]. In detail, amplicon sequence 178 variants (ASVs) were generated using the DADA2 pipeline (via q2-dada2), which includes 179 removal of low-quality reads, denoising, merging, and removal of bimeras [36]. Chimeric 180 ASVs were further filtered out using a reference-based approach with VSEARCH [37] (via 181 g2-vsearch) and SILVA database (v132) [38]. Taxonomic assignment of ASVs was also 182 performed with VSEARCH [37] (via q2-feature-classifier) and SILVA (v132) [38]. Finally,

7

non-bacterial ASVs were removed (via *q2-feature-table*). QIIME 2 outputs were transferred
to the R environment [39] using the *qiime2R* R package [40] and analyzed for microbiota
profiling with custom R scripts as detailed below.

186 Microbiota and statistical analyses

187 The total number of reads of the sample with the lowest number of reads (3,578 188 reads) among the samples included in the microbiota profiling analyses was used as C_{min} for 189 Scaling with Ranked Subsampling (SRS) normalization prior to diversity analyses [41]. 190 Diversity was measured by the Gini-Simpson index [42] using the *phyloseg* R package [43]. 191 Longitudinal diversity variations were evaluated by calculating diversity resistance, 192 resilience, and stability [44, 45] (see Additional file 3: Supplementary methods). 193 Compositional dissimilarity between samples was measured by the weighted UniFrac 194 distance [46] using the rbiom R package [47]. Longitudinal compositional variations were 195 evaluated by calculating compositional stability (see Additional file 3). Multiple linear 196 regression was used to evaluate whether antibiotic usage was associated with diversity 197 stability and compositional stability (see Additional file 3). Recovery to baseline composition 198 was defined as distance between samples collected at preconditioning and 30 days after 199 engraftment < 0.5.

Taxonomic nomenclature was homogenized prior to all taxonomic analyses (see Additional file 3). Taxa relative abundance plots included only the most relevant genera according to criteria specified in figure legends. Differential abundance analysis was performed using ANCOM-BC [48] with genera present in ≥25% of the samples being compared. Genera abundance differences between groups at q-value < 0.05 (Bonferroni correction) were considered statistically significant, including ANCOM-BC structural zeroes.

Associations between oral microbiota composition recovery or clinical parameters with allo-HSCT outcomes were determined using univariate Cox proportional-hazards regression [49] or univariate Fine-Gray competing risk regression [50]. Cox models were used to evaluate overall survival and progression-free survival, while Fine-Gray models were

used to evaluate the risk of transplant-related death (with relapse mortality as competing risk) and the risk of underlying disease relapse (with transplant-related mortality as competing risk). Multivariate analysis was used to evaluate oral microbiota composition recovery and correct for clinical parameters significantly associated with the outcome (Pvalue < 0.05) in the univariate analysis. Patients experiencing the event before oral microbiota composition recovery evaluation were excluded from univariate and multivariate analyses.

217 Results

218 Samples collected and sequencing output

219 We collected samples from three oral sites (GCF, OM, and SB) at five timepoints 220 during allo-HSCT: preconditioning (P), aplasia (A), engraftment (E), 30 days after 221 engraftment (E30), and 75 days after engraftment (E75). Since most patients were 222 discharged shortly after engraftment, the exact date of sample collection varied for E30 (20-223 45 days after engraftment) and E75 (60–131 days after engraftment) samples, as indicated 224 in Fig. S3. Premature death after allo-HSCT hampered the collection of the E30 sample for 225 patient #3 and E75 samples for patients #1, #2, #3, #21, and #31 (Fig. S3). In addition, the 226 E75 sample from patient #9 was excluded due to low DNA yield. Overall, 444 samples were 227 successfully processed and sequenced for microbiota profiling.

We generated a total of 53,253,725 V3V4 16S rRNA reads (median per sample: 104,230.5; range: 2,059–502,409; Fig. S2b). After filtering, 31,343,619 reads (59%; Fig. S2c–d) were retained (median per sample: 63,075.5; range: 87–310,082; Fig. S2e), corresponding to 4,046 ASVs. Using SRS curves [51] (Fig. S4), we established a minimum sequencing depth cutoff of 3,000 reads and 4 low-depth samples were excluded from further analysis (patient #1, OM, P; #5, OM, E; #6, OM, E; #25, SB, E). We proceeded to profile the oral microbiota during allo-HSCT with 440 samples.

9

235 Compositional differences between oral microbiotas during allo-HSCT and after 236 engraftment

237 We first assessed microbiota compositional differences between oral sites at each 238 allo-HSCT timepoint. Visually, all three oral microbiotas occupied a similar compositional 239 space throughout allo-HSCT (Fig. 1a). Nevertheless, similarly to what is observed in healthy 240 adults [4], each oral site contained a significantly different microbiota composition at P 241 (PERMANOVA, GCF vs. OM: P-value = 0.001; GCF vs. SB: P-value = 0.002; OM vs. SB: P-242 value = 0.018). Noteworthy, these differences progressively diminished in subsequent 243 timepoints until E30 and were partially recovered at E75 (Fig. 1b). Calculation of the 244 minimum compositional distance between oral sites for each patient confirmed lower 245 compositional distance between sites after P (Fig. 1c).

246 Differential abundance analysis at genus level using ANCOM-BC revealed a similar 247 picture (Fig. 1d). As expected, all three oral microbiotas showed many distinguishing genera 248 at P. For example, we observed a higher abundance of Actinomyces in the SB as compared 249 to GCF and a higher abundance of Solobacterium in the OM as compared to SB (Fig. S5). 250 Actinomyces spp. are early colonizers of the SB with a crucial role in ecological succession 251 during SB maturation [52]. On the other hand, Solobacterium moorei, the only known 252 species in the Solobacterium genus, is a halitosis-associated bacteria typically found in the 253 tongue dorsum [53], a site contemplated in OM samples. However, a smaller number of 254 differentially abundant genera was observed in subsequent timepoints, with a slight increase 255 in the number of differentially abundant genera between sites at E75, illustrated by the 256 reappearance of Solobacterium as an OM-associated genus (Fig. S5).

In short, our data indicate that compositional differences between oral microbiotas are reduced during allo-HSCT, being only partially recovered several weeks after engraftment.

10

260 Oral microbiota dynamics during allo-HSCT and after engraftment

We next characterized microbiota diversity dynamics at each oral site during allo-HSCT and after engraftment. As previously shown for OM [25] and SB [24], GCF presented a stepped decline in diversity up to E (Fig. 2a). By extending this analysis to the postengraftment period for all oral sites, we observed a gradual recovery of diversity, with baseline levels almost fully reestablished around E75.

266 We then applied key concepts from ecology [45] for a more in-depth characterization 267 of diversity dynamics during allo-HSCT. By considering allo-HSCT as a perturbation relieved 268 immediately after engraftment, we calculated for each patient diversity resistance (inversely 269 proportional to the diversity loss up to E), resilience (rate of diversity gain after E), and 270 stability (combined effect of resistance and resilience) to allo-HSCT (Fig. S6a; see Additional 271 File 3). GCF showed higher diversity resistance than OM and SB (Fig. 2b), in line with the less pronounced loss of diversity observed in this oral site at E (Fig. S6b). All oral sites 272 273 presented equivalent levels of diversity resilience and stability (Fig. 2b), in line with the 274 similar levels of diversity after engraftment observed for all oral sites (Fig. S6b).

275 Next, we characterized compositional changes in each oral site during allo-HSCT 276 and after engraftment. The compositional distance to P centroid increased up to E and decreased in the post-engraftment period, indicating a displacement from and posterior 277 278 recovery to baseline compositions (Fig. 1c). However, when comparing the compositional 279 distance from P to all other timepoints using PERMANOVA tests, we observed that GCF and 280 SB post-engraftment samples still showed significantly different compositions after 281 engraftment compared to P, while OM samples more fully recovered their preconditioning 282 state (Fig. 1d). Finally, in analogy to diversity stability, we calculated the compositional 283 stability for each patient (see Additional File 3). As observed for diversity stability, all oral 284 sites showed equivalent levels of compositional stability (Fig. S6c).

11

Our data indicate that allo-HSCT transiently damages oral microbiotas diversity and composition, but each oral site responds differently to the perturbations associated with allo-HSCT.

288 Oral taxa abundances during allo-HSCT and after engraftment

289 The loss of differences between microbiotas of distinct oral sites and the 290 displacement from initial compositions observed during allo-HSCT point out to a complex 291 compositional dynamics that likely involves many bacterial taxa and thus can be better 292 appreciated by longitudinal taxonomic composition analysis at each specific site. As 293 expected, all oral sites presented high relative abundance of commensal bacteria at P (Fig. 294 3a; Fig. S7). For instance, Veillonella and Streptococcus, genera with high relative 295 abundance in all oral sites of healthy adults [4], occupied either the first or second position in 296 terms of mean relative abundance at P in all three oral sites (Fig. 3b). However, there were 297 several changes in the ranking of the most abundant taxa (on average) across timepoints 298 (Fig. 3b; Fig. S7), pointing to drastic taxonomic composition changes during allo-HSCT. 299 There are some noteworthy examples, such as *Streptococcus* in SB, which went from first in 300 the relative abundance ranking at P to the eleventh position at E. Interestingly, 301 Streptococcus recovered its initial ranking position after engraftment (first position at E30 302 and E75). On the other hand, some non-commensals genera were close to absent in P and 303 only emerged in the subsequent timepoints. For instance, *Enterococcus* and *Lactobacillus*, 304 both potentially pathogenic genera in the oral microbiota [54, 55], showed low mean relative 305 abundance at P but were among the most abundant genera in all sites at E.

Differential abundance analysis at genus level using ANCOM-BC with P as reference for comparisons confirmed these results and showed several additional differentially abundant genera (Fig. 3c). The number of differentially abundant genera at each timepoint was consistent with the compositional displacement and recovery aforementioned, with a maximum of differentially abundant genera at E (Fig. S8). Although there were considerably fewer differentially abundant genera after engraftment, some differences persisted. For

12

instance, we observed a decreased abundance of *Catonella* in OM and SB, and of Tannerella in GCF at E75, suggesting a long-lasting reduction of these genera caused by allo-HSCT.

In summary, we observed that the dynamics of some commensal bacteria reproduce the same pattern of displacement during allo-HSCT and recovery after engraftment observed for the overall community. We also observed the emergence of opportunistic potentially pathogenic genera during the most perturbed allo-HSCT phase which are capable of colonizing all three oral sites and likely contribute to the loss of compositional differences between oral microbiotas observed after preconditioning.

321 Emergence of opportunistic genera and allo-HSCT complications

322 The emergence of opportunistic genera during allo-HSCT can be more rigorously 323 quantified by assessing taxa blooms, defined as a taxon relative abundance increase from 324 <1% at P to dominance levels (\geq 30%) at any subsequent timepoint. We have previously 325 shown, by analyzing this same cohort, blooms of specific genera occurring in SB during A 326 and E [24]. We now extended this analysis to other oral sites and to the post-engraftment 327 period. Overall, we detected 81 blooms, involving 22 genera and 27/31 patients. All oral sites 328 showed several blooming events, but SB blooms were more frequent (SB: n = 35; GCF: n = 329 24: OM: n = 22; Fig. 4a) and significantly more prevalent (SB: 23/31; GCF: 14/31; MO: 330 16/30; chi-square test, P-value = 0.022). Blooms typically occurred at E (53% of events; Fig. 331 4b) and were rapidly resolved in the post-engraftment period.

Lactobacillus (15%), *Enterococcus* (12%), and *Staphylococcus* (10%) were the genera most frequently observed in blooming events in the oral microbiota during allo-HSCT (Fig. 4c). But oral sites differed in the genera typically associated with blooms (Fig. 4d). SB showed mainly *Enterococcus* (7 events) or *Lactobacillus* (6) blooms, while GCF showed mostly *Staphylococcus* (4) or *Lactobacillus* (4) blooms. In contrast, OM blooms showed a less clear signal of blooming genera. Nevertheless, some patients presented concomitant blooms of the same genus in all oral sites.

13

339 We noticed that many of the blooming genera are potentially pathogenic for allo-340 HSCT recipients. For instance, Staphylococcus genus contains species related to several 341 infections, including hospital-acquired pneumonia [56], an allo-HSCT complication with 15-342 30% incidence [57]. Therefore, we evaluated whether blooming events in the oral microbiota 343 were associated with respiratory infections in our cohort. Between P and E75, only 3/31 344 patients presented bacterial respiratory infections (patients #1, #2, and #7). All three patients 345 showed blooms of genera in the oral microbiota during allo-HSCT. Specifically, patient #1 346 presented blooms of Enterococcus (in GCF and SB at E) and Acetobacter (in GCF and SB 347 at E30), patient #2 presented blooms of Stenotrophomonas (in all oral sites at E) and 348 Mycoplasma (in GCF at E), and patient #7 presented blooms of Mycoplasma (in OM and SB 349 at E). Interestingly, patients #1 and #2 presented blooms of the same genus identified in the 350 respiratory microbiological exam of their tract samples: Enterococcus and 351 Stenotrophomonas, respectively. Importantly, these blooms preceded the clinical 352 manifestation of the respiratory infection by one and two weeks, respectively, suggesting a 353 potential oral origin for the bacteria associated with the respiratory infections in these cases. 354 On the other hand, patient #7 developed a respiratory infection caused by Escherichia coli 355 between E30 and E75, which was unrelated to the blooms detected for this patient.

Given the apparent translocation of abundant oral bacteria to the respiratory tract in 356 357 our cohort and the well-known association between intestinal dominance and bacteremia 358 during allo-HSCT [58], we also tested whether blooming events in the oral microbiota were 359 associated with bacteremia events. Positive blood cultures for bacteria were detected for 360 15/31 patients between P and E75. We did not find an association between oral microbiota 361 blooms and altered odds of bacteremia (Fisher's exact test, GCF bloom: OR = 3.17, P-value 362 = 0.156; OM bloom: OR = 2.25, P-value = 0.299; SB bloom: OR = 0.92, P-value = 1; any 363 site bloom: OR = 3.12, P-value = 0.600). We detected a single case in which the blooming 364 of a genus in the oral microbiota preceded a bacteremia event with the same genus 365 involved. In detail, patient #14 presented blooms of Enterococcus in GCF and SB at A, 366 which preceded positive blood cultures for *Enterococcus* by 1.5 weeks.

14

367 Overall, we observed that blooms of opportunistic genera occur frequently in oral 368 microbiota during allo-HSCT, especially in SB. The examples described suggest oral 369 microbiota blooms during allo-HSCT may trigger translocation of oral microbes to the 370 respiratory tract (as often happens during oral microbiome dysbiosis [56]) and cause 371 respiratory infections in allo-HSCT recipients.

372 Impact of antibiotic usage on oral microbiota dynamics

373 To investigate the impact of antibiotic usage on oral microbiota dynamics and 374 blooming events during allo-HSCT, we analyzed antibiotic usage data between P and E30 375 (see Materials and Methods). Antibiotic usage varied widely across patients in terms of 376 length of therapy (LOT range: 0–58 days; median: 15.5 days) and days of therapy (DOT 377 range: 0–112 days; median: 22 days) (Table S1). Overall, 17 antibiotic agents (range: 0-10; 378 median: 3), spanning 12 distinct antibiotic classes (range: 0-9; median: 3 antibiotics) were 379 administered to our patients. The antibiotics administered to each patient are illustrated in 380 Fig. 5a. Most patients received cefepime (73%) and meropenem (63%), making 381 cephalosporins and carbapenems the most frequently used antibiotic classes: 73% and 382 63%, respectively (Fig. S9a). Glycopeptides and penicillins were also used in a considerable proportion of patients: 60% and 23%, respectively. All other antibiotic classes were used by 383 384 less than 17% of our patients (Fig. S9b).

First, to assess the effect of antibiotic usage in microbiota dynamics, we modeled 385 386 diversity stability (which incorporates diversity resistance and resilience) and compositional stability using antibiotic usage information (Table S2). We found that DOT significantly 387 predicted diversity stability during allo-HSCT for all oral sites, with prolonged use of antibiotic 388 389 therapy associated with lower diversity stability. However, the use of specific antibiotic 390 classes was not associated with altered diversity stability (Table S2). On the other hand, 391 DOT was not a predictor of compositional stability, but glycopeptide usage was significantly 392 associated with decreased SB compositional stability (Table S2). In addition, we found non-393 significant associations at P-value < 0.1 between other antibiotic classes and decreased

15

394 compositional stability in GCF (cephalosporins and penicillins) and SB (cephalosporins), 395 while OM compositional stability was clearly less impacted by antibiotic usage during allo-396 HSCT (Table S2).

We next tested whether blooms at different oral sites were associated with antibiotic usage. E75 blooms were not considered in this analysis since our antibiotic usage survey focused on the period between P and E30 (see Materials and Methods). With one exception (glycopeptides and GCF blooms), the use of specific antibiotic classes was not associated with blooms, but patients experiencing blooms showed higher LOT and DOT (Fig. 5b), although it is not clear whether a more extended period under antibiotic therapy was the cause or consequence of the blooms.

404 GCF blooms were significantly associated not only with LOT and DOT but also with 405 the use of glycopeptides (Fisher's exact test, odds ratio (OR) = 15.65, P-value = 0.006, P-406 adjusted = 0.025), which enabled the investigation of the relation between the timing of 407 glycopeptide usage and GCF blooming events. GCF blooms occurred in 12 patients up to 408 E30, out of which 11 used glycopeptides (vancomycin and/or teicoplanin) between P and 409 E30. Notably, 10/11 patients that used glycopeptides and experienced GCF blooms received 410 glycopeptides a few days before or during the interval in which the bloom was detected, 411 indicating that glycopeptide usage during allo-HSCT may cause blooms of genera in the oral 412 microbiota.

413 The relationship between glycopeptide usage and blooming events and its 414 consequences can be illustrated by the genera composition trajectories and antibiotic usage 415 timeline of patients #1 and #2. Patient #2 experienced Stenotrophomonas blooms in all sites at E, which occurred during the administration of vancomycin (Fig. 5c). Two weeks after 416 417 these blooms, patient #2 developed a respiratory infection caused by Stenotrophomonas 418 maltophilia, detected in microbiological exams of respiratory tract samples (e.g., 419 bronchoalveolar lavage). Despite the intensification in the use of antibiotics. 420 Stenotrophomonas levels only rose in the oral microbiota after E, reaching staggering levels 421 at E30 (>95% relative abundance in all oral sites). Analysis at ASV level revealed that

16

422 Stenotrophomonas ASVs were absent in patient #2 at P (relative abundance = 0% in all oral 423 sites). At A, during the first course of vancomycin (Fig. 5c), a Stenotrophomonas maltophilia 424 ASV emerged in the SB (relative abundance = 0.02%). This ASV would later be responsible 425 for the blooms at E and the domination observed at E30. Taken together, these results 426 suggest that the use of vancomycin during allo-HSCT allowed the emergence and the bloom 427 of pathogenic Stenotrophomonas maltophilia in oral microbiota, which later translocated to 428 the respiratory tract, causing a respiratory infection. Patient #1 presented a similar picture 429 (Fig. S10), with the use of vancomycin followed by *Enterococcus* blooms and a subsequent 430 respiratory infection caused by Enterococcus faecium. Notably, patients #1 and #2 died 431 before E75, with death causes at least partially associated with their respiratory infections.

In summary, greater time of antibiotic exposure was associated with lower microbiota diversity stability and blooms in all oral sites. Glycopeptide usage was associated with lower microbiota compositional stability in SB and, although direct evidence is lacking, it seems causally linked to some of the blooming events.

436 Inter-patient variability in oral microbiota dynamics during allo-HSCT and after

437 engraftment

438 To investigate inter-patient variability in oral microbiota dynamics during allo-HSCT 439 and after engraftment, we assessed longitudinal changes in oral microbiota in a patient-440 centered analysis. Although most patients presented high diversity stability, which was 441 achieved either by having high resistance, high resilience, or a balance between the two, 442 some patients presented low diversity stability and even negative resilience values (Fig. 6a). 443 indicating loss of diversity after E. Curiously, this inter-patient variability was not due to 444 different levels of baseline diversity, since diversity at P was not correlated with diversity 445 resistance, resilience, nor stability (Fig. S11a). Compositional stability was also not 446 correlated with diversity levels at P (Fig. S11b)

447 In addition, when representing samples from all timepoints using Principal Coordinate 448 Analysis (PCoA), we noticed that confidence intervals for E samples were larger, indicating

17

449 considerable inter-patient compositional variability under perturbation (Fig. S11c). To confirm 450 this observation, we determined the most perturbed timepoint by quantifying the extent of 451 compositional shifts between timepoints. As presented in Fig. 6b, compositional changes 452 were more pronounced between A and E. Next, we evaluated inter-patient compositional 453 variability at each timepoint either by assessing the compositional distance between samples 454 and the respective timepoint centroid (Fig. 6c) or by calculating for each timepoint all 455 pairwise compositional distances (Fig. 6d). Both results confirmed maximum inter-patient 456 compositional variability at E under maximized perturbation, underscoring that allo-HSCT 457 modifies oral microbiota differently for each patient.

458 Finally, we investigated if this variability in oral microbiota dynamics during allo-HSCT 459 influenced oral microbiota recovery after engraftment. Although our results indicate that post-460 engraftment samples overall occupy a similar compositional space in comparison to P, this 461 does not necessarily imply that patients recover their respective initial oral microbiota 462 compositions after engraftment. In order to evaluate oral microbiota compositional recovery 463 per patient, we analyzed the compositional distance from P for each patient and each site 464 during allo-HSCT and after engraftment. Interestingly, we noted that even though most 465 patients showed a recovery trajectory after engraftment, some did not (Fig. 6e).

466 Our data indicate a marked inter-patient variability in oral microbiota dynamics in 467 response to allo-HSCT. Despite oral microbiotas as a whole resembling preconditioning 468 microbiotas after allo-HSCT, patients differ in their ability to recover their initial oral 469 microbiota composition.

470 Recovery of oral microbiota composition and allo-HSCT outcomes

To investigate whether oral microbiota recovery after allo-HSCT was associated with allo-HSCT outcomes we grouped our patients based on their ability to recover their preconditioning composition. We calculated the compositional distance between P and E30, and classified patients as recoverers (distance <0.5) or non-recoverers (distance \geq 0.5). We further illustrate these contrasting recovery behaviors using PCoA with compositional

trajectories of a representative OM recoverer and of an OM non-recoverer (Fig. 7a). PCoAs
for each patient are presented in Fig. S12. Overall, 77, 69, and 77% of our patients
recovered their initial GCF, OM, and SB microbiota composition after engraftment,
respectively (Fig. 7b).

480 Next, we used univariate analysis to investigate whether oral microbiota recovery 481 after allo-HSCT was associated with allo-HSCT outcomes (Table S3; Fig. S13). Interestingly, 482 OM recovery was associated with prolonged overall survival (OS: hazard ratio (HR) [95% 483 confidence interval (CI)] = 0.17 [0.05–0.52], P-value = 0.002; Fig. 7c), prolonged 484 progression-free survival (PFS; HR [95% CI] = 0.06 [0.01-0.34], P-value = 0.001; Fig. 7d), 485 and a lower risk of underlying disease relapse (HR [95% CI] = 0.20 [0.06-0.69], P-value = 486 0.011; Fig. 7e). OM recovery, however, was not associated with altered risk of transplant-487 related death and GCF recovery or SB recovery were not associated with allo-HSCT 488 outcomes (Table S3; Fig. S13).

489 To identify possible confounding variables, we used univariate analysis to investigate 490 whether clinical parameters (including antibiotic usage; Table S1) were associated with allo-491 HSCT outcomes (Table S4-7). We found that disease risk index (DRI), conditioning 492 intensity, and DOT were significantly associated with OS (Table S4). DRI was also 493 associated with PFS (Table S5) and the risk of underlying disease relapse (Table S6). We 494 then used a multivariate analysis to assess whether OM recovery was an independent 495 predictor of allo-HSCT outcomes (Table S8). In all cases, OM recovery remained 496 significantly associated with prolonged OS (HR [95% CI] = 0.09 [0.02-0.35], P-value < 497 0.001; Fig. 7f), prolonged PFS (HR [95% CI] = 0.09 (0.02–0.49), P-value = 0.005; Fig. 7g), 498 and with a lower risk of underlying disease relapse (HR [95% CI] = 0.19 [0.06–0.55], P-value = 0.003; Fig. 7h). Taken together, these results robustly indicate that OM recovery at E30 is 499 500 an independent biomarker of better allo-HSCT outcomes.

501 Underlying factors associated with oral mucosa microbiota recovery

502 Given the relevant associations between OM recovery and allo-HSCT outcomes, we 503 searched for underlying factors associated with OM recovery. OM recovery was not 504 associated with clinical parameters such as age, underlying disease, and graft source (Table 505 S9). The usage of specific antibiotic classes, LOT, and DOT between P and E30 were also 506 not associated with OM recovery (Table S9; Fig. S14a). In addition, OM recoverers and non-507 recoverers showed similar intervals between stem-cell infusion and engraftment (Fig. S14b).

508 We also evaluated whether OM microbiota characteristics could be related to OM 509 recovery. OM recoverers did not show higher OM diversity at E30 (Fig. 8a), indicating OM 510 non-recoverers did not necessarily possess dysbiotic OM microbiotas at E30. In line with 511 this, OM blooms throughout allo-HSCT were not more frequent among OM non-recoverers 512 (Fisher's exact test, OR = 4.07, P-value = 0.13). On the other hand, OM recoverers showed 513 higher OM diversity at P and E (Fig. 8a). In fact, there was a significant negative correlation 514 between OM diversity at P and the compositional distance between P and E30 (Fig. 8b). 515 This effect was not observed for GCF and SB (Fig. 8b).

516 Lastly, we investigated if earlier reconstitution of blood cell counts was associated 517 with OM recovery (see Additional File 3; Fig. 8c). Blood cell counts at P or E were not associated with OM recovery. Interestingly, however, OM recoverers showed higher 518 519 leukocyte counts at E30, which is mostly due to significantly higher neutrophil and 520 lymphocyte counts in this group. Furthermore, normal (within reference values) leukocyte 521 counts at E30 were more frequently observed among OM recoverers compared to OM nonrecoverers (16/20 vs. 3/9, respectively; Fisher's exact test, P-value = 0.032) and OM 522 523 recoverers presented higher leukocyte counts throughout one year after allo-HSCT 524 compared to non-recoverers due to the combined contribution of higher neutrophil, 525 lymphocyte, and monocyte counts (Fig. S14c).

526 In summary, we found independent (blood cell counts) and non-independent (OM 527 microbiota at P) parameters to illuminate the differences between OM recoverers and non-

20

528 recoverers. OM recovery was associated with higher diversity at P, indicating more diverse 529 OM communities are more competent in recovering their pre-perturbation compositions. In 530 addition, OM recoverers showed higher leukocyte counts at E30, suggesting an association 531 between OM microbiota composition recovery and earlier immune system reconstitution.

532 Discussion

533 The anatomical complexity of the oral cavity provides a multitude of physicochemical 534 environments for microbes to thrive [1, 3]. Although several dozen core bacterial genera 535 inhabit all oral compartments, different species occupy each oral niche, meaning oral 536 microbes are site-specialists that compose distinct microbiotas in each oral environment [1, 537 59]. We and others have previously reported the impact of allo-HSCT in oral microbiotas and 538 their associations with allo-HSCT complications and outcomes [22-26, 30]. However, these 539 studies analyzed single oral sites and were mostly limited to the peri-engraftment period of 540 allo-HSCT. To our knowledge, this is the first study to evaluate the impact of allo-HSCT in 541 the microbiota of various oral sites simultaneously during and after allo-HSCT.

542 We found that the microbiota of all oral sites was severely damaged by allo-HSCT, 543 but each site responded differently to the perturbations associated with allo-HSCT. 544 Compositional differences between oral sites were lost during allo-HSCT and partially 545 recovered after engraftment. Oral microbiota injury was marked by loss of diversity and 546 emergence of opportunistic potentially pathogenic genera. Notably, these opportunistic 547 genera could colonize all three oral sites and likely contributed to the loss of compositional 548 differences between oral microbiotas observed after conditioning. Colonization by 549 opportunistic genera was more common at E, explaining the higher compositional variability 550 and lower diversity observed at E, which we found to be the most perturbed allo-HSCT 551 phase for all oral sites. This is in line with the Anna Karenina Principle applied to host-552 associated microbiomes [60], which states that more diverse communities tend to be more

21

553 compositionally similar, while perturbed communities tend to occupy several alternative 554 dysbiotic states.

555 Blooms of opportunistic genera were associated with prolonged antibiotic exposure 556 and the use of glycopeptides. This association is clinically relevant in the allo-HSCT setting 557 since glycopeptide-resistant bacteria (e.g., vancomycin-resistant enterococci) are a common 558 cause of infections in the hospital environment [61], especially in immunosuppressed 559 individuals. In addition, we observed that, in some cases, oral microbiota blooms preceded 560 respiratory infections caused by the blooming bacteria, linking the oral microbiota dynamics 561 during allo-HSCT to a common allo-HSCT complication [62], probably due to translocation of 562 oral bacteria to the respiratory tract through aspiration [56]. Similarly to our study, Thänert et 563 al. (2019) showed pathobiont blooms in the gut microbiota often preceded urinary tract 564 infections, but, as observed here, not all blooms were associated with subsequent infection 565 [63]. Interestingly, even though the mouth is a highly vascularized organ and the existence of 566 an oral-blood translocation axis has been proposed [64], we did not find a clear association 567 between oral bacteria blooms and bacteremia events during allo-HSCT.

568 Respiratory infections following blooms were caused by *E. faecium* in patient #1 and 569 S. maltophilia in patient #2. S. maltophilia colonization has been reported in 7% of allo-HSCT 570 recipients and is associated with higher non-relapse mortality risk due to higher odds of 571 invasive S. maltophilia infections [65]. Our results highlight that nosocomial bacteria such as S. maltophilia can colonize the oral cavity during allo-HSCT. These results point to the 572 573 importance of maintaining oral health during allo-HSCT not only to prevent oral but also 574 distal complications (e.g., hospital-acquired pneumonia) [56]. Furthermore, our results suggest that tracking drastic oral microbiota changes during allo-HSCT may guide early 575 576 interventions to prevent infections. This will be especially useful when the causative agent is 577 not a common respiratory pathogen such as in the case of *E. faecium* [66].

578 Longitudinal analysis of oral microbiota diversity and composition showed post-579 transplant oral microbiotas were overall similar to preconditioning microbiotas, but patient-580 level analysis showed that 23-31% of the patients did not recover their preconditioning

22

microbiota composition. Variability in gut microbiota recovery following a perturbation has been previously described [67, 68], including after allo-HSCT, where most patients (>90%) were unable to recover their initial gut microbiota composition [68]. The higher proportion of patients that recovered their preconditioning composition in our study suggests that the oral microbiota is more resilient to the perturbations associated with allo-HSCT than the gut microbiota. This result is in line with a previous study showing that the oral microbiota is more resilient than the gut microbiota to antibiotic perturbation [69].

588 Pre-perturbation microbiota characteristics, such as the presence of keystone 589 bacteria, influence microbiota recovery [70]. Here, we found that patients that recovered their 590 OM microbiota composition after allo-HSCT showed higher preconditioning OM diversity, 591 indicating that more diverse OM microbiotas are more resilient to allo-HSCT. Our results 592 converge on the insurance hypothesis, which proposes that high-diversity communities are 593 less susceptible to perturbations [71]. Interestingly, in our study, OM compositional recovery 594 was not associated with the use of specific antibiotics nor with the duration of antibiotic 595 exposure. This is possibly because OM microbiota composition is not impacted by 596 antibiotics, as evidenced by the lack of associations between antibiotic usage and OM 597 compositional stability. Host genetics, reestablishment of normal diet, and reconstitution of 598 the immune system are other possible drivers of microbiota recovery after allo-HSCT. Here, 599 we showed that leukocyte blood counts at E30 were higher in patients that recovered their 600 OM microbiota composition, indicating a close link between early immune system 601 reconstitution and oral microbiota recovery. We can speculate that immune reconstitution 602 allows stricter control of microbiota compositions (e.g., via immunoglobulin A [72]), which, 603 along with reestablishment of microbial environment (e.g., normal diet), supports the 604 recovery of the initial OM microbiota composition [73, 74].

The ability to recover the OM initial microbiota composition was associated with better allo-HSCT outcomes. However, it is unclear if OM microbiota recovery is just a consequence or also a driver of early immune reconstitution, thus having a causal role in the improved outcomes following allo-HSCT. Evidence from gut microbiota studies indicates that

23

609 the latter hypothesis is plausible [75]. For instance, recent studies have shown that specific 610 gut microbes are associated with immune cell dynamics post-allo-HSCT [15, 76]. Similarly, 611 Miltiadous et al. (2022) found that higher peri-engraftment gut microbiota diversity was 612 associated with higher lymphocyte counts 100 days after transplant [77]. In addition, murine 613 model experiments showed that gut microbiota supports immune reconstitution by allowing a 614 higher dietary energy uptake [78]. Most importantly, in a controlled randomized clinical trial, 615 patients who received autologous fecal microbiota transplant after allo-HSCT showed higher 616 leukocyte counts 100 days after engraftment, indicating recovery of the gut microbiota has a 617 causal role in facilitating immune system reconstitution [15]. If this causal relationship 618 extends to the oral microbiota, the use of therapeutic interventions to promote oral health 619 and microbiota recovery in allo-HSCT recipients, such as oral microbiota transplants [79], 620 could potentially improve allo-HSCT outcomes.

621 An important limitation of our study is its small sample size, which did not allow 622 underlying disease stratification to parse the effect of different diseases on oral microbiota 623 dynamics. Still, the longitudinal design, assessment of different oral sites, and evaluation of 624 a Brazilian cohort (a population underrepresented in human microbiome studies [80]) with 625 extensive metadata publicly available are strengths of our study that should be highlighted. 626 Also, to better address the influence of oral bacteria in immune cell dynamics, future studies 627 will have to combine high temporal resolution oral microbiota data with more deeply 628 phenotyped immune cell counts (e.g., flow cytometry data). In addition, since 16S rRNA 629 amplicon sequencing has limited taxonomic resolution, further studies should ideally be 630 performed using shotgun metagenomic sequencing, as this would allow strain-level 631 dynamics tracking. Finally, here and previously [24, 25], we showed that associations 632 between gut microbiota and allo-HSCT outcomes broadly extend to the oral microbiota. 633 However, studies with synchronous gut and oral microbiota profiling will be necessary to 634 decipher how these microbiotas are linked during allo-HSCT, especially considering the 635 higher translocation of oral bacteria along the oral-gut axis during disease [81].

24

636 Conclusions

The oral cavity is the ultimate doorway for microbes entering the human body. We analyzed oral microbiotas dynamics in allo-HSCT recipients and showed that microbiota injury and recovery patterns were highly informative on allo-HSCT complications and outcomes. Our results highlight the importance of tracking recipient's microbiotas changes during allo-HSCT to improve our understanding of allo-HSCT biology, safety, and efficacy.

642 Availability of data and materials

The bioinformatics pipeline used to process the sequencing data, the R scripts used to run the analyses and generate the figures, and all clinical metadata (anonymized) necessary to reproduce these results are available at https://github.com/vitorheidrich/oralmicrobiota-hsct. Raw sequencing data have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB53914. Some samples (analyzed in past studies) were deposited previously in ENA at EMBL-EBI under accession numbers: PRJEB42862, PRJEB49175.

650 **Abbreviations**

- 651 A: Aplasia
- 652 Allo-HSCT: Allogeneic hematopoietic stem-cell transplant
- 653 ASV: Amplicon Sequence Variant
- 654 CI: Confidence interval
- 655 DOT: Days of therapy
- 656 DRI: Disease Risk Index
- 657 E: Engraftment
- 658 E30: 30 days after engraftment
- 659 E75: 75 days after engraftment
- 660 E. faecium: Enterococcus faecium

- 661 GCF: Gingival crevicular fluid
- 662 HR: Hazard ratio
- 663 LOT: Length of therapy
- 664 OM: Oral mucosa
- 665 OR: Odds ratio
- 666 OS: Overall survival
- 667 P: Preconditioning
- 668 PFS: Progression-free survival
- 669 SB: Supragingival biofilm
- 670 S. maltophilia: Stenotrophomonas maltophilia
- 671 SRS: Scaling with ranked subsampling

672 References

- 1. Welch JLM, Ramírez-Puebla ST, Borisy GG. Oral Microbiome Geography: Micron-Scale
 Habitat and Niche. Cell Host Microbe. 2020;28:160–8.
- 2. Rosier BT, Marsh PD, Mira A. Resilience of the Oral Microbiota in Health: Mechanisms
 That Prevent Dysbiosis. J Dent Res. 2018;97:371–80.
- 3. Proctor DM, Relman DA. The Landscape Ecology and Microbiota of the Human Nose,Mouth, and Throat. Cell Host Microbe. 2017;21:421–32.
- 4. Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, et al. Composition of
 the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat
 and stool samples. Genome Biol. 2012;13:R42.
- 5. Tuganbaev T, Yoshida K, Honda K. The effects of oral microbiota on health. Science.
 2022;376:934–6.
- 684 6. Takahashi N, Nyvad B. The Role of Bacteria in the Caries Process: Ecological 685 Perspectives. J Dent Res. 2011;90:294–303.
- 7. Ng E, Tay JRH, Balan P, Ong MMA, Bostanci N, Belibasakis GN, et al. Metagenomic
 sequencing provides new insights into the subgingival bacteriome and aetiopathology of
 periodontitis. J Periodontal Res. 2021;56:205–18.
- 8. Gaffen SL, Moutsopoulos NM. Regulation of host-microbe interactions at oral mucosal
 barriers by type 17 immunity. Sci Immunol. 2020;5:eaau4594.
- 9. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas
 gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with
 small-molecule inhibitors. Sci Adv. 2019;5:eaau3333.
- 694 10. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la

medRxiv preprint doi: https://doi.org/10.1101/2022.11.18.22282520; this version posted November 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 695 Camara R, et al. Indications for haematopoietic cell transplantation for haematological 696 diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone 697 Marrow Transplant. 2022;57:1217–39.
- 11. Jenq RR, van den Brink MRM. Allogeneic haematopoietic stem cell transplantation:
 individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10:213–21.
- 700 12. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell 701 transplantation: one size does not fit all. Blood. 2014;124:344–53.
- 13. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of Allogeneic Hematopoietic Stem
 Cell Transplantation. Annu Rev Immunol. 2007;25:139–70.
- 14. Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al.
 Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic
 Stem Cell Transplantation. Clin Infect Dis. 2020;71:226–36.
- 15. Schluter J, Peled JU, Taylor BP, Markey KA, Smith M, Taur Y, et al. The gut microbiota
 is associated with immune cell dynamics in humans. Nature. 2020;588:303–7.
- 709 16. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health710 and disease. Cell Res. 2020;30:492–506.
- 17. Ervin SM, Ramanan SV, Bhatt AP. Relationship Between the Gut Microbiome andSystemic Chemotherapy. Dig Dis Sci. 2020;65:874–84.
- 18. Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, et al. The impact of pelvic radiotherapy
 on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review.
 Radiat Oncol Lond Engl. 2021;16:187.
- 716 19. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H.
 717 Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020;10.
- 20. Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stemcell transplantation. Nat Rev Cancer. 2018;18:283–95.
- 21. Sen T, Thummer RP. The Impact of Human Microbiotas in Hematopoietic Stem Cell andOrgan Transplantation. Front Immunol. 2022;13.
- 22. Ames NJ, Barb JJ, Ranucci A, Kim H, Mudra SE, Cashion AK, et al. The oral microbiome
 of patients undergoing treatment for severe aplastic anemia: a pilot study. Ann Hematol.
 2019;98:1351–65.
- 23. Shouval R, Eshel A, Dubovski B, Kuperman AA, Danylesko I, Fein JA, et al. Patterns of
 salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem
 cell transplantation. Blood Adv. 2020;4:2912–7.
- 728 24. Heidrich V, Bruno JS, Knebel FH, de Molla VC, Miranda-Silva W, Asprino PF, et al.
 729 Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host
 730 Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2021;12.
- 25. de Molla VC, Heidrich V, Bruno JS, Knebel FH, Miranda-Silva W, Asprino PF, et al.
 Disruption of the oral microbiota is associated with a higher risk of relapse after allogeneic
 hematopoietic stem cell transplantation. Sci Rep. 2021;11:17552.
- 26. Laheij AMGA, Rozema FR, Brennan MT, von Bültzingslöwen I, van Leeuwen SJM,
 Potting C, et al. Long-Term Analysis of Resilience of the Oral Microbiome in Allogeneic Stem
 Cell Transplant Recipients. Microorganisms. 2022;10:734.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.18.22282520; this version posted November 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 27. Liu C, Frank DN, Horch M, Chau S, Ir D, Horch EA, et al. Associations between acute
 gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell
 transplant recipients and donors. Bone Marrow Transplant. 2017;52:1643–50.
- 28. Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland
 JB, et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease.
 Science. 2019;366:1143–9.
- Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, et al. Microbiota as
 Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med.
 2020;382:822–34.
- 746 30. Oku S, Takeshita T, Futatsuki T, Kageyama S, Asakawa M, Mori Y, et al. Disrupted
 747 tongue microbiota and detection of nonindigenous bacteria on the day of allogeneic
 748 hematopoietic stem cell transplantation. PLOS Pathog. 2020;16:e1008348.
- 31. Stanić Benić M, Milanič R, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A, et
 al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic
 review and international multidisciplinary consensus procedure. J Antimicrob Chemother.
 2018;73 suppl_6:vi50–8.
- 32. Wang H, Altemus J, Niazi F, Green H, Calhoun BC, Sturgis C, et al. Breast tissue, oral
 and urinary microbiomes in breast cancer. Oncotarget. 2017;8:88122–38.
- 33. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, et al. Evaluation of
 general 16S ribosomal RNA gene PCR primers for classical and next-generation
 sequencing-based diversity studies. Nucleic Acids Res. 2013;41:e1.
- 758 34. Heng Li. seqtk: Toolkit for processing sequences in FASTA/Q formats.
- 35. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
 Nat Biotechnol. 2019;37:852–7.
- 36. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2:
 High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–3.
- 37. Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open sourcetool for metagenomics. PeerJ. 2016;4:e2584.
- 38. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA
 ribosomal RNA gene database project: improved data processing and web-based tools.
 Nucleic Acids Res. 2013;41:D590–6.
- 39. R Core Team. R: A language and environment for statistical computing. R Found StatComput Vienna Austria. 2021.
- 40. Jordan E. Bisanz. qiime2R: Importing QIIME2 artifacts and associated data into Rsessions. 2018.
- 41. Beule L, Karlovsky P. Improved normalization of species count data in ecology by
 scaling with ranked subsampling (SRS): application to microbial communities. PeerJ.
 2020;8:e9593.
- 42. Simpson EH. Measurement of Diversity. Nature. 1949;163:688–688.
- 43. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysisand Graphics of Microbiome Census Data. PLOS ONE. 2013;8:e61217.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.18.22282520; this version posted November 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .
- 779 44. Orwin KH, Wardle DA. New indices for quantifying the resistance and resilience of soil 780 biota to exogenous disturbances. Soil Biol Biochem. 2004;36:1907-12.
- 781 45. Shade A, Peter H, Allison S, Baho D, Berga M, Buergmann H, et al. Fundamentals of 782 Microbial Community Resistance and Resilience. Front Microbiol. 2012;3.
- 783 46. Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. UniFrac: an effective 784 distance metric for microbial community comparison. ISME J. 2011;5:169-72.
- 785 47. Daniel P. Smith. rbiom: Read/Write, Transform, and Summarize "BIOM" Data. 2022.
- 786 48. Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. Nat 787 Commun. 2020;11:3514.
- 788 49. Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B Methodol. 789 1972;34:187-202.
- 50. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing 790 791 Risk. J Am Stat Assoc. 1999;94:496-509.
- 792 51. Heidrich V, Karlovsky P, Beule L. 'SRS' R Package and 'g2-srs' QIIME 2 Plugin: 793 Normalization of Microbiome Data Using Scaling with Ranked Subsampling (SRS). Appl Sci. 794 2021;11:11473.
- 795 52. Kolenbrander PE, Palmer RJ, Periasamy S, Jakubovics NS. Oral multispecies biofilm 796 development and the key role of cell-cell distance. Nat Rev Microbiol. 2010;8:471-80.
- 797 53. Barrak I, Stájer A, Gajdács M, Urbán E. Small, but smelly: the importance of 798 Solobacterium moorei in halitosis and other human infections. Heliyon. 2020;6:e05371.
- 799 54. Komiyama EY, Lepesqueur LSS, Yassuda CG, Samaranayake LP, Parahitiyawa NB, 800 Balducci I, et al. Enterococcus Species in the Oral Cavity: Prevalence, Virulence Factors and 801 Antimicrobial Susceptibility. PLOS ONE. 2016;11:e0163001.
- 802 55. Caufield PW, Schön CN, Saraithong P, Li Y, Argimón S. Oral Lactobacilli and Dental 803 Caries: A Model for Niche Adaptation in Humans. J Dent Res. 2015;94 9 suppl:110S-118S.
- 804 56. Dong J, Li W, Wang Q, Chen J, Zu Y, Zhou X, et al. Relationships Between Oral 805 Microecosystem and Respiratory Diseases. Front Mol Biosci. 2022;8.
- 806 57. Gudiol C, Sabé N, Carratalà J. Is hospital-acquired pneumonia different in transplant 807 recipients? Clin Microbiol Infect. 2019;25:1186-94.
- 808 58. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal 809 Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic 810 Stem Cell Transplantation. Clin Infect Dis. 2012;55:905–14.
- 811 59. Mark Welch JL, Dewhirst FE, Borisy GG. Biogeography of the Oral Microbiome: The 812 Site-Specialist Hypothesis. Annu Rev Microbiol. 2019;73:335-58.
- 813 60. Zaneveld JR, McMinds R, Vega Thurber R. Stress and stability: applying the Anna 814 Karenina principle to animal microbiomes. Nat Microbiol. 2017;2:1-8.
- 815 61. Cookson BD, Macrae MB, Barrett SP, Brown DFJ, Chadwick C, French GL, et al. 816 Guidelines for the control of glycopeptide-resistant enterococci in hospitals. J Hosp Infect. 817 2006;62:6-21.
- 818 62. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious 819 complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.18.22282520; this version posted November 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 821 63. Thänert R, Reske KA, Hink T, Wallace MA, Wang B, Schwartz DJ, et al. Comparative 822 Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of 823 Urinary Tract Infections. mBio. 2019;10:e01977-19.
- 824 64. Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, Emgård JEM, et al. Colon Cancer-825 Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon 826 Tumors via the Circulatory System. Front Cell Infect Microbiol. 2020;10.
- 827 65. Scheich S, Koenig R, Wilke AC, Lindner S, Reinheimer C, Wichelhaus TA, et al. 828 Stenotrophomonas maltophilia colonization during allogeneic hematopoietic stem cell 829 transplantation is associated with impaired survival. PLOS ONE. 2018;13:e0201169.
- 830 66. Li F, Wang Y, Sun L, Wang X. Vancomycin-resistant Enterococcus faecium pneumonia 831 in a uremic patient on hemodialysis: a case report and review of the literature. BMC Infect 832 Dis. 2020;20:167.
- 833 67. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the 834 human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci. 2011;108 835 supplement 1:4554-61.
- 836 68. Vaitkute G, Panic G, Alber DG, Faizura-Yeop I, Cloutman-Green E, Swann J, et al. 837 Linking gastrointestinal microbiota and metabolome dynamics to clinical outcomes in 838 paediatric haematopoietic stem cell transplantation. Microbiome. 2022;10:89.
- 839 69. Zaura E, Brandt BW, Teixeira de Mattos MJ, Buijs MJ, Caspers MPM, Rashid M-U, et al. 840 Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the 841 Salivary Microbiome versus Long-Term Microbial Shifts in Feces. mBio. 2015;6:e01693-15.
- 842 70. Chng KR, Ghosh TS, Tan YH, Nandi T, Lee IR, Ng AHQ, et al. Metagenome-wide 843 association analysis identifies microbial determinants of post-antibiotic ecological recovery in 844 the gut. Nat Ecol Evol. 2020;4:1256-67.
- 845 71. Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the intestinal 846 microbiota influences health and disease. Nat Rev Microbiol. 2017;15:630-8.
- 847 72. Hooper LV, Littman DR, Macpherson AJ. Interactions Between the Microbiota and the 848 Immune System. Science. 2012;336:1268-73.
- 849 73. Martino C, Dilmore AH, Burcham ZM, Metcalf JL, Jeste D, Knight R. Microbiota 850 succession throughout life from the cradle to the grave. Nat Rev Microbiol. 2022;20:707–20.
- 851 74. Ng KM, Aranda-Díaz A, Tropini C, Frankel MR, Treuren WV, O'Loughlin CT, et al. 852 Recovery of the Gut Microbiota after Antibiotics Depends on Host Diet, Community Context, 853 and Environmental Reservoirs, Cell Host Microbe, 2019;26:650-665.e4.
- 854 75. Fiorenza S, Turtle CJ. Associations between the Gut Microbiota, Immune Reconstitution, 855 and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. Immunometabolism. 856 2021;3:e210004.
- 857 76. Ingham AC, Kielsen K, Cilieborg MS, Lund O, Holmes S, Aarestrup FM, et al. Specific 858 gut microbiome members are associated with distinct immune markers in pediatric 859 allogeneic hematopoietic stem cell transplantation. Microbiome. 2019;7:131.
- 860 77. Miltiadous O, Waters NR, Andrlová H, Dai A, Nguyen CL, Burgos da Silva M, et al. Early 861 intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. Blood. 2022;139:2758-69. 862
- 863 78. Staffas A, Silva MB da, Slingerland AE, Lazrak A, Bare CJ, Holman CD, et al. Nutritional

- 864 Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone 865 Marrow Transplantation in Mice. Cell Host Microbe. 2018;23:447-457.e4.
- 79. Nath S, Zilm P, Jamieson L, Kapellas K, Goswami N, Ketagoda K, et al. Development
 and characterization of an oral microbiome transplant among Australians for the treatment of
 dental caries and periodontal disease: A study protocol. PLOS ONE. 2021;16:e0260433.
- 869 80. Abdill RJ, Adamowicz EM, Blekhman R. Public human microbiome data are dominated 870 by highly developed countries. PLOS Biol. 2022;20:e3001536.
- 871 81. Jin S, Wetzel D, Schirmer M. Deciphering mechanisms and implications of bacterial 872 translocation in human health and disease. Curr Opin Microbiol. 2022;67:102147.

873 Acknowledgements

874 Not applicable.

875 Funding

- 876 VH was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP,
- process no. 13996-0/2018). FHK was supported by FAPESP (process no. 16854-4/2015).

878 Author information

879 Authors and Affiliations

- 880 Centro de Oncologia Molecular, Hospital Sírio-Libanês, São Paulo, SP, Brazil
- 881 Vitor Heidrich, Franciele H. Knebel, Julia S. Bruno, Wanessa Miranda-Silva, Paula F.
- 882 Asprino, Eduardo R. Fregnani, Anamaria A. Camargo
- 883 Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo,
- 884 SP, Brazil
- 885 Vitor Heidrich
- 886 Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, SP, Brazil
- 887 Luciana Tucunduva, Yana Novis
- 888 Hospital Nove de Julho, Rede DASA, São Paulo, SP, Brazil
- 889 Vinícius C. de Molla, Celso Arrais-Rodrigues
- 890 Universidade Federal de São Paulo, São Paulo, SP, Brazil

- 891 Vinícius C. de Molla, Celso Arrais-Rodrigues
- 892 Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo/Instituto do
- 893 Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil
- 894 Vanderson Rocha

895 Contributions

EFR and AAC designed the study. VCM, LT, VR, YN, and CAR recruited and clinically evaluated volunteers. VCM collected data from clinical records. WMS collected oral samples. FHK processed most of the samples. FHK and PFA performed the sequencing. VH and AC conceptualized the analysis. VH performed all bioinformatics and statistical analyses. VH, JSB, and AAC contributed to the interpretation of results. VH and AAC wrote the original draft of the manuscript. VH, JSB, VCM, PFA, CAR, and AAC reviewed and edited the manuscript. All authors read and approved the final manuscript.

903 Corresponding author

904 Correspondence to Anamaria A. Camargo.

905 Ethics declarations

906 Ethics approval and consent to participate

- 907 This study was approved by the Ethics Committee of Hospital Sírio-Libanês (#HSL 2016-08),
- 908 in line with the Declaration of Helsinki. All patients provided their written informed consent to909 participate.

910 **Consent for publication**

911 Not applicable.

912 Competing interests

913 The authors declare that they have no competing interests.

914 Figure legends

915 Figure 1

916 a Principal Coordinate Analysis (PCoA) of microbiota distances (weighted UniFrac) between oral sites 917 for each timepoint. Ellipsoids indicate 95% confidence intervals. b Magnitude (PERMANOVA F) of 918 distances (weighted UniFrac) between oral sites per timepoint. c Minimum distance (weighted 919 UniFrac) between oral sites within patients per timepoint. Mann-Whitney U test was used with 920 preconditioning (P) as the reference for comparisons. d Number of differentially abundant genera 921 (ANCOM-BC) between oral sites per timepoint. GCF, gingival crevicular fluid; OM, oral mucosa; SB, 922 supragingival biofilm; A, aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days after 923 engraftment; **, P-value < 0.01; ***, P-value < 0.001.

924 Figure 2

925 a Diversity (Gini-Simpson) per timepoint for each oral site. Mann-Whitney U test was used with 926 preconditioning (P) as the reference for comparisons. **b** Diversity resistance, resilience, and stability 927 (see Methods) per oral site. Mann-Whitney U test was used. Distance to P centroid (weighted 928 UniFrac) per timepoint for each oral site. Mann-Whitney U test was used with P as the reference for 929 comparisons. d Magnitude (PERMANOVA F) of distances (weighted UniFrac) between P and other 930 timepoints for each site. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival biofilm; A, 931 aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days after engraftment; *, P-value < 932 0.05; **, P-value < 0.01; ***, P-value < 0.001; ****, P-value < 0.0001.

933 Figure 3

a Mean genera relative abundances (RA) per timepoint for each oral site. Genera with >2% mean RA
in any combination of oral site and timepoint are shown. b Mean genera RA ranking per timepoint for
each oral site. Top-10 genera are shown. c Differentially abundant genera (ANCOM-BC) between P
and other timepoints for each site. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival
biofilm; P, preconditioning; A, aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days

939 after engraftment; *, q-value < 0.05; **, q-value < 0.01; ***, q-value < 0.001; z, ANCOM-BC structural
940 zero.

941 Figure 4

a-c Proportion of blooming events per oral site (a), timepoint (b) and genus (c). d Number of blooming
events per genus in each oral site. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival
biofilm; A, aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days after engraftment.

945 Figure 5

946 a Antibiotic agents used by each patient between preconditioning (P) and 30 days after engraftment 947 (E30). **b** Time of antibiotic administration (LOT: length of therapy; DOT: days of therapy) among 948 patients showing and not showing blooms between P and E30. c Patient #2: genera relative 949 abundance dynamics for each oral site (top) and antibiotic usage timeline (bottom). Genera with >1% 950 mean relative abundance in any combination of oral site and timepoint are shown. GCF, gingival 951 crevicular fluid: OM, oral mucosa; SB, supragingival biofilm; A, aplasia; E, engraftment; E75, 75 days 952 after engraftment; SC, stem-cell; vanc, vancomycin; tige, tigecycline; tazo, piperacillin tazobactam; 953 poli, polymyxin B; mero, meropenem; line, linezolid.

954 Figure 6

955 a Relationship between diversity resistance, resilience, and stability values calculated for each 956 patient. b Extent of compositional shifts (weighted UniFrac) between consecutive timepoints (adjusted 957 for the time in days between timepoints) for each oral site. The line indicates the median value per 958 interval. c Distance (weighted UniFrac) to timepoint centroid per timepoint for each oral site. Mann-959 Whitney U test was used with preconditioning (P) as the reference for comparisons. d Pairwise 960 distances (weighted UniFrac) per timepoint (all-against-all) for each oral site. Mann-Whitney U test 961 was used with P as the reference for comparisons. e Distance to P (weighted UniFrac) at engraftment 962 (E) and 30 days after engraftment (E30) for each patient for each oral site. The thick line indicates the 963 median value at each timepoint. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival 964 biofilm; A, aplasia; E75, 75 days after engraftment; **, P-value < 0.01; ***, P-value < 0.001; ****, P-965 value < 0.0001.

966 Figure 7

34

967 a Principal Coordinate Analysis (PCoA) with representative microbiota trajectories of an oral mucosa 968 (OM) recoverer and non-recoverer. b Recovery classifications per site for each patient. Patient #1 OM 969 recovery could not be evaluated due to missing samples. c-d Kaplan-Meier curves comparing overall 970 survival (c) and progression-free survival (d) among OM recoverers (R) and non-recoverers (NR). e 971 Cumulative incidence curves of relapse among OM R and OM NR. f-h multivariate analysis for overall 972 survival (f), progression-free survival (g), and risk of relapse (h). Each model includes OM recovery 973 and the clinical variables that are relevant for each outcome. P, preconditioning; A, aplasia; E, 974 engraftment; E30, 30 days after engraftment; E75, 75 days after engraftment; HR, hazard ratio; DRI, 975 disease risk index; DOT, days of antibiotic therapy; Cond Int, conditioning intensity.

976 Figure 8

a Diversity (Gini-Simpson) among oral mucosa (OM) recoverers and non-recoverers for each
timepoint. Mann-Whitney U test was used. b Correlation between diversity (Gini-Simpson) at
preconditioning (P) and the compositional distance (weighted UniFrac) between P and 30 days after
engraftment (E30) for each oral site. Spearman's rank correlation test was used. c Blood cell counts
among OM recoverers and non-recoverers per timepoint for each blood cell type. Red dotted
horizontal lines indicate normal counts (within reference values). Mann-Whitney U test was used. A,
aplasia; E, engraftment; E75, 75 days after engraftment; *, P-value < 0.05; **, P-value < 0.01.

984 Supplementary information

985

Additional file 1: Timelines of antibiotic usage.

986 Antibiotic usage timelines for each patient in relation to stem-cell infusion. Red 987 dashed line indicates preconditioning sampling. Red solid line indicates stem-cell infusion. 988 Blue solid line indicates stem-cell engraftment. Blue dashed line indicates 30 days after 989 engraftment sampling. clav, amoxicillin clavulanate; tazo, piperacillin tazobactam; amox, 990 amoxicillin; cefe, cefepime; mero, meropenem; metr, metronidazole; ceft, ceftriaxone; vanc, 991 vancomycin; teic, teicoplanin; cipr, ciprofloxacin; levo, levofloxacin; doxi, doxycycline; ampi, 992 ampicillin; clar, clarithromycin; bact, sulfamethoxazole trimethoprim; erta, ertapenem; poli, 993 polymyxin b; dapt, daptomycin; line, linezolid; tige, tigecycline; amic, amikacin.

994 Additional file 2: Supplementary tables and figures.

995 Supplementary material with 9 tables and 14 figures.

996 Additional file 3: Supplementary methods.

997 Supplementary text to the Materials and methods section.















